万邦德(002082) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥279,349,841.02, a decrease of 38.26% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥38,552,845.01, representing a decline of 143.17% year-over-year[5] - Basic earnings per share were -¥0.0629, down 143.08% from ¥0.1500 in the same quarter last year[5] - Total revenue for Q3 2023 decreased by 66.52% to CNY 14,966,149.74 compared to CNY 44,704,201.25 in the same period last year[12] - Net profit for Q3 2023 was a loss of CNY 8,690,319.50, compared to a profit of CNY 138,628,805.04 in Q3 2022[22] - The total comprehensive income for Q3 2023 was -22,085,081.24 CNY, a significant decrease from 136,802,046.02 CNY in the same period last year[23] - The basic and diluted earnings per share for Q3 2023 were both -0.0114 CNY, compared to 0.2386 CNY in Q3 2022[23] Cash Flow and Liquidity - The net cash flow from operating activities was -¥144,605,877.01, an improvement of 34.93% compared to the previous year[5] - Cash and cash equivalents decreased by 32.18% to ¥317,117,469.95, primarily due to payments for project costs and product registration fees[11] - The company’s cash and cash equivalents decreased to CNY 317,117,469.95 from CNY 467,618,833.18 at the beginning of the year[17] - Cash flow from operating activities showed a net outflow of -144,605,877.01 CNY, improving from -222,218,627.93 CNY year-over-year[25] - Cash inflow from financing activities was 951,431,185.70 CNY, compared to 459,135,656.86 CNY in the previous year, indicating a strong increase in financing[25] - The net cash flow from investing activities was -149,708,522.93 CNY, slightly worse than -132,856,406.96 CNY in the same period last year[25] - The cash and cash equivalents at the end of Q3 2023 were 307,045,111.70 CNY, down from 537,697,036.72 CNY at the end of Q3 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,380,325,963.89, an increase of 3.85% from the end of the previous year[5] - The company's total assets increased to CNY 4,380,325,963.89 in Q3 2023 from CNY 4,218,038,019.21 in Q3 2022[19] - Total liabilities rose to CNY 1,657,095,212.87 in Q3 2023, up from CNY 1,399,786,396.12 in the previous year[19] - The company’s total assets include accounts receivable of CNY 937,840,504.30, down from CNY 1,052,711,870.82 at the beginning of the year[17] Operational Metrics - The company experienced a significant decline in sales prices due to national medical insurance cost control and centralized procurement policies, impacting overall profit levels[5] - Total operating revenue for Q3 2023 was CNY 1,017,909,499.80, a decrease of 14.0% compared to CNY 1,183,636,278.66 in Q3 2022[21] - Total operating costs for Q3 2023 were CNY 1,045,153,909.62, slightly up from CNY 1,043,180,236.93 in the same period last year[21] - The company reported a significant increase in inventory, which rose to CNY 307,942,322.49 from CNY 283,152,095.33 year-over-year[18] - Total operating cash outflows were 1,054,098,656.69 CNY, compared to 1,432,053,320.85 CNY in the previous year, reflecting improved cost management[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,531[14] - The largest shareholder, Wanbangde Group Co., Ltd., holds a 31.37% stake, amounting to 193,426,693 shares[14] - The company completed a capital reduction, decreasing registered capital from CNY 618,222,829 to CNY 616,689,055[16] Government and Financial Support - The company reported a government subsidy of ¥2,060,531.05 in the current period, an increase compared to previous periods[8] - Financial expenses increased by 79.05% to CNY 31,657,608.64 due to higher financing amounts compared to the previous year[12] - The company reported a significant reduction in credit impairment losses by 73.02% to CNY -5,016,209.83[12] Research and Development - Research and development expenses for Q3 2023 were CNY 38,904,284.30, down from CNY 44,375,326.41 in Q3 2022[22] Audit Status - The company has not undergone an audit for the Q3 2023 report[28]